The development of Zongertinib for HER2-mutant NSCLC

Abstract excerpt

Human epidermal growth factor receptor 2 ( HER2 ) mutations are rare in NSCLC and the only FDA approved agent until recently, was trastuzumab deruxtecan in the second line setting. HER2 mutated NSCLC has historically shown worse prognosis compared to other NSCLC and represent an unmet clinical need. Almost 50 % of patients with HER2 -mutated non-small cell lung cancer (NSCLC) have brain metastases at diagnosis....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Chronic Lymphocytic Leukemia Research
• Share to Chronic Myeloid Leukemia Treatments
• Share to HER2/EGFR in Cancer Research